Discontinuation of the development of a transdermal patch formulation of Teribone™ human parathyroid hormone

January 31, 2014
Asahi Kasei Pharma Corp.

Asahi Kasei Pharma Corporation (headquarters: Tokyo, Japan; President: Toshio Asano) and Zosano Pharma, Inc. (headquarters: Fremont, California, USA; CEO: Vikram Lamba) have reached a decision to discontinue the development of a transdermal patch formulation of Teribone™ human parathyroid hormone using microprojection technology from Zosano, and have terminated the relevant license agreement between Asahi Kasei Pharma and Zosano.

Asahi Kasei Pharma has advanced the development of the transdermal patch formulation in Japan under the license agreement with Zosano, but results of the Phase I clinical trial did not meet the go/no-go decision criteria established by Asahi Kasei Pharma to proceed to Phase II. It was therefore determined that the development of this formulation could not continue.

Moving forward, Asahi Kasei Pharma remains committed to further developments of new formulations of Teribone™ that enhance usability for patients.


News

Adobe Readeris required to view these PDF files.


page top